Editorial Commentary
DESTINY-Breast01 Trial: trastuzumab deruxtecan in previously treated HER2 positive breast cancer
Published online: 31 October 2021Guideline
Chinese society of clinical oncology (CSCO) Breast Cancer Guidelines 2022
Published online: 30 April 2022Original Article
Occurrence and distribution of bone metastases in 984 metastatic breast cancer patients
Published online: 31 January 2021Review Article
Innovation drug approvals based on a bridging study: from concept to practice
Published online: 31 January 2022Clinical Practice Guideline
Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024
Published online: 25 July 2024Original Article: Case Series
Risk-reducing surgery in PALB2 mutations carriers with breast cancer: a case series and literature review
Published online: 31 October 2022Review Article
A narrative review of the clinical development of CDK4/6 inhibitor abemaciclib in breast cancer
Published online: 31 January 2022Original Article
Five-year survival in luminal breast cancer patients: relation with intratumoral activity of proteasomes
Published online: 30 July 2022Guideline
Guidelines of Chinese Society of Clinical Oncology (CSCO) on Diagnosis and Treatment of Breast Cancer (2020 version)
Published online: 31 October 2020Review Article
A narrative review of the current landscape and future perspectives of HER2-targeting antibody drug conjugates for advanced breast cancer
Published online: 31 October 2021Review Article
Reprogramming of fatty acid metabolism in breast cancer: a narrative review
Published online: 31 January 2021Review Article
Potential biomarkers of resistance to CDK4/6 inhibitors: a narrative review of preclinical and clinical studies
Published online: 30 April 2021Review Article
